Neuroendocrine tumours and their microenvironment

Lotte D. de Hosson(University Medical Center Groningen), Annemiek Walenkamp(University Medical Center Groningen)

Cancer Immunology Immunotherapy

April 8, 2020

10.1007/s00262-020-02556-1

Cited by 26

Related Papers

TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with <sup>89</sup>Zr-Fresolimumab PET

|Journal of Nuclear Medicine|2015|99

Defining EGFR amplification status for clinical trial inclusion

|Neuro-Oncology|2019|44

Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour

|European Journal of Nuclear Medicine and Molecular Imaging|2011|42

Myocardial Metastases on 6-[18F] fluoro-L-DOPA PET/CT: A Retrospective Analysis of 116 Serotonin Producing Neuroendocrine Tumour Patients

|PLoS ONE|2014|24

Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma

|European Journal of Cancer|2021|20